Etoposide Side Effects: Short-Term and Long-Term Risks

Etoposide, a chemotherapy drug used against cancers ranging from testicular and lung cancer to lymphomas and certain childhood tumors, carries a side-effect profile dominated by drops in blood cell counts, hair loss, nausea, and fatigue. Because it works by damaging DNA in rapidly dividing cells, it inevitably hits healthy tissues that also divide quickly, particularly bone marrow, the gut lining, and hair follicles. Most side effects are temporary and manageable with supportive care, but a few rarer risks, including a small chance of treatment-related leukemia years later, deserve attention.

How Etoposide Works and Why Side Effects Follow

Etoposide belongs to a class of drugs that target an enzyme called topoisomerase II. This enzyme normally helps untangle DNA during cell division. Etoposide traps the enzyme mid-action, leaving behind breaks in the DNA strand that the cell cannot repair, which triggers cell death.¹ The problem is that the drug cannot distinguish cancer cells from normal cells that happen to be dividing rapidly. Bone marrow cells, which churn out new blood cells every day, are especially vulnerable. So are the cells lining the digestive tract and the cells that produce hair. This shared vulnerability is the root cause of the side effects most patients experience.

Falling Blood Counts

The single most clinically important side effect of etoposide is myelosuppression, meaning the drug suppresses the bone marrow’s ability to produce blood cells. White blood cells tend to drop the most, which raises the risk of infection. Red blood cells and platelets can also fall, leading to anemia and easier bruising or bleeding.

The drop in white blood cells does not happen immediately. Research modeling the drug’s effect on white cells found a characteristic lag of roughly four and a half days before counts begin to decline, with the total duration below baseline lasting about three weeks.² The lowest point, often called the nadir, typically falls somewhere between days 10 and 14 after a dose, though the exact timing varies with the regimen. Counts then recover gradually, and most patients return to normal before their next treatment cycle. During the nadir, though, even a minor infection can become serious, so oncology teams monitor blood work closely and sometimes prescribe growth-factor injections to speed recovery.

Nausea, Vomiting, and Mouth Sores

Nausea and vomiting are among the most commonly reported complaints, though they are generally classified as moderate rather than severe with etoposide alone.³ Modern anti-nausea medications have made these symptoms much more controllable than they were decades ago, and many patients tolerate treatment without major gastrointestinal distress. That said, etoposide is almost always combined with other chemotherapy agents, and the combination can amplify nausea beyond what etoposide alone would cause.

Mucositis, or inflammation and sores inside the mouth and along the GI tract, is another recognized side effect. Mild cases involve tenderness or redness in the mouth; more severe cases can lead to painful ulcers that make eating and swallowing difficult. Good oral hygiene, gentle mouthwashes, and staying well hydrated help reduce the severity. In high-dose regimens, particularly those used before bone marrow transplants, mucositis can become a significant quality-of-life issue.

Hair Loss

Etoposide is consistently associated with significant hair loss. In studies evaluating chemotherapy-induced alopecia, etoposide was grouped alongside taxanes and anthracyclines as a drug class with a high likelihood of causing hair thinning or complete hair loss.⁴ Hair loss typically begins within a few weeks of starting treatment and can affect the scalp, eyebrows, eyelashes, and body hair. The good news is that it is almost always reversible: hair regrows once treatment ends, though the texture or color sometimes changes temporarily.

Scalp cooling systems, which constrict blood vessels in the scalp to reduce the amount of drug reaching hair follicles, have shown some success in preserving hair during chemotherapy. One study found that the majority of patients using an effective cooling system maintained adequate hair preservation, even when treated with drugs known to cause heavy hair loss. Whether scalp cooling is practical depends on the treatment setting and the specific regimen, and not all oncology centers offer it.

Reactions During Infusion

When etoposide is given intravenously, some patients develop infusion-related reactions. These can range from mild flushing and itching to more serious drops in blood pressure, difficulty breathing, or chest tightness. A study examining ten years of pediatric data across two hospitals found that infusion reactions occurred in roughly 1% of patients overall, though rates climbed to several percent at one hospital after a change in infusion filter practices.⁵ Of the patients who had a reaction, a large proportion were successfully re-treated with etoposide by slowing the infusion rate or adding premedications like antihistamines and steroids.

The standard intravenous formulation of etoposide contains solvents, including polysorbate 80 and polyethylene glycol, that are suspected of contributing to some hypersensitivity reactions. An alternative formulation, etoposide phosphate, dissolves in water and eliminates these additives.⁶ Etoposide phosphate can also be given more quickly and at higher concentrations, which is more convenient. However, hypersensitivity reactions have still been reported with the phosphate version, suggesting that the drug molecule itself can trigger immune responses in some people, not just the solvents.⁷

Oral Versus Intravenous Etoposide

Etoposide is available in both an oral capsule and an intravenous form. The oral version absorbs about half of the dose into the bloodstream, and that absorption becomes less predictable at higher doses.⁸ Factors like kidney function, liver function, other medications, and even the nausea caused by the drug itself can change how much actually gets absorbed. When the oral form is given over several consecutive days, its effectiveness appears comparable to IV treatment for many cancers, and it obviously spares patients the inconvenience of repeated infusion visits.

The side-effect profiles of oral and IV etoposide are broadly similar, since the active drug is the same once it enters the bloodstream. The main difference is practical: IV infusions carry the risk of infusion reactions and require clinic visits, while oral dosing avoids those issues but introduces the uncertainty of variable absorption. If nausea or vomiting is severe enough to prevent a patient from keeping the capsule down, the effective dose drops unpredictably, which complicates both efficacy and toxicity management.

Risk of Secondary Leukemia

The most serious long-term risk of etoposide is the development of treatment-related leukemia. Because the drug works by disrupting topoisomerase II activity on DNA, it can occasionally cause lasting genetic damage in bone marrow cells that survive treatment. This damage frequently involves a specific gene on chromosome 11 called MLL. Rearrangements of MLL are strongly associated with a form of secondary acute myeloid leukemia (AML) that carries a particularly grim prognosis.⁹

The absolute risk depends heavily on the total cumulative dose. In a study of patients treated for advanced germ cell tumors who received high cumulative doses of etoposide, the cumulative incidence of secondary AML was about 1.3% at a median follow-up of just over four years. Compared with the age-matched general population, these patients had a dramatically elevated risk of developing AML.¹⁰ Secondary leukemia from etoposide tends to appear within two to three years of treatment, which is earlier than treatment-related leukemias caused by other drug classes like alkylating agents. This relatively short latency means that the first few years of follow-up after treatment are the most important window for monitoring.

One case report further illustrated this risk in an unusual context: a patient with a brain tumor who received long-term etoposide both into the spinal fluid and orally eventually developed secondary AML.¹¹ While a single case cannot establish a rate, it reinforces that the leukemia risk is tied to cumulative drug exposure regardless of the route used.

Who Faces Higher Toxicity

Not everyone clears etoposide from the body at the same rate, and slower clearance means the drug lingers longer and causes more damage to healthy tissues. Kidney function is a major factor. Patients with impaired kidneys clear etoposide significantly more slowly, resulting in higher drug exposure and more severe drops in blood cell counts. In one study, patients with elevated creatinine had notably lower neutrophil nadirs compared to those with normal kidney function.¹²

Age also matters. Among patients with otherwise normal lab values, those older than 65 showed reduced drug clearance and correspondingly greater toxicity. Liver function adds another layer: patients with elevated liver enzymes tended to have higher levels of the unbound, active form of the drug in their blood, which drives toxicity. Since etoposide is heavily bound to a blood protein called albumin, patients with low albumin levels, whether from liver disease, malnutrition, or other causes, end up with more free drug circulating and are at greater risk of side effects.

A recent case report put this complexity into sharp focus. A patient with cystic fibrosis, liver cirrhosis, and pre-existing low blood counts who needed etoposide for testicular cancer also happened to be taking several other medications that slow down the same liver enzyme responsible for breaking down etoposide. The oncology team started at half the standard dose and monitored drug levels in the blood, adjusting carefully across treatment cycles to balance effectiveness against toxicity.¹³ Cases like this are unusual, but they show why oncologists check organ function before each cycle and why dose adjustments are common.

Nerve Damage

Peripheral neuropathy, the tingling, numbness, or pain in the hands and feet that many people associate with chemotherapy, is not a headline side effect of etoposide at standard doses. It shows up more clearly at the very high doses used before bone marrow transplants. In a review of 142 patients who received high-dose etoposide before transplant, six developed a new sensory neuropathy that began two to eight weeks after treatment. Symptoms were moderate to severe and improved slowly over months. All six had also previously received vincristine, a drug well known for causing nerve damage, making it hard to pin the blame entirely on etoposide.¹⁴

Animal studies have shown that etoposide at high doses can cause degeneration of sensory nerve cells in the dorsal root ganglia, the clusters of nerve cell bodies along the spine, along with damage to the nerve fibers extending from them.¹⁵ At standard clinical doses, though, neuropathy from etoposide alone is uncommon enough that when it appears, clinicians usually investigate whether another drug in the regimen or an underlying condition is responsible.

Lung and Heart Effects

Etoposide can, on rare occasions, cause drug-induced pneumonitis, an inflammation of the lung tissue that produces shortness of breath, cough, and characteristic hazy patches on imaging. Case reports describe patients who developed interstitial lung infiltrates and respiratory failure during etoposide treatment, with biopsy findings consistent with drug-induced injury. At least one patient improved rapidly with steroids but relapsed when re-exposed to etoposide, strongly implicating the drug as the cause.¹⁶ The challenge is that lung cancer patients receiving etoposide may also be experiencing disease progression, radiation-related lung injury, or infections, any of which can mimic drug-induced pneumonitis. Clinicians have to consider etoposide toxicity in any patient who develops new or worsening breathing problems during treatment.¹⁷

Cardiovascular toxicity from etoposide is even rarer and poorly characterized. There is limited evidence linking the drug to heart problems, though isolated case reports exist of myocardial ischemia occurring during treatment.¹⁸ Because etoposide is almost always given alongside other drugs, particularly cisplatin, which has its own cardiovascular baggage, teasing out etoposide’s independent contribution is difficult. For most patients, cardiac monitoring beyond what is standard for the overall regimen is not considered necessary.

Effects on Fertility

Etoposide is most commonly associated with fertility concerns in the context of testicular cancer treatment, where it is a backbone of the standard BEP regimen (bleomycin, etoposide, and cisplatin). The combination damages sperm-producing cells and can significantly impair spermatogenesis. Animal studies of BEP showed reduced testicular weight, germ cell depletion, and a threefold increase in germ cell death during treatment. Fertility was not completely lost, but litter sizes shrank and early pregnancy losses increased.¹⁹

The encouraging finding from the same research is that most of the damage was reversible. By nine weeks after treatment ended, germ cell death rates had returned to normal and most fertility markers had recovered. However, some evidence of damage to the earliest sperm precursor cells persisted, suggesting that full reproductive recovery takes time and may not be complete in all individuals. For young men about to undergo etoposide-containing chemotherapy, sperm banking before treatment remains the standard recommendation.

Fatigue and Quality of Life After Treatment

Beyond the acute side effects that cluster around each treatment cycle, many cancer survivors who received etoposide-based chemotherapy report lingering fatigue, sometimes lasting months or years after treatment ends. This chronic fatigue is a recognized phenomenon across many chemotherapy regimens, and researchers have noted that its impact on quality of life in survivors of germ cell tumors, a group heavily treated with etoposide-containing protocols, has not been thoroughly evaluated.²⁰ Studies in testicular cancer survivors, the largest population treated with BEP, have identified long-term effects on energy levels, hearing (from cisplatin), and sometimes cognitive sharpness, though separating the contribution of each drug in a multi-agent regimen is complicated.

The broader point is worth keeping in mind: the side effects of etoposide do not exist in a vacuum. The drug is almost always part of a cocktail, and the combination shapes the patient’s experience far more than any single agent. A patient receiving etoposide alongside cisplatin and bleomycin for testicular cancer has a very different side-effect landscape from someone getting etoposide paired with carboplatin for lung cancer. Your oncology team tailors monitoring, supportive medications, and dose adjustments to the specific regimen and your individual risk factors, including age, kidney and liver function, and what other drugs you are taking.